CLOZAPINE TREATMENT OF SCHIZOPHRENIC OUTPATIENTS

Project: Research project

Description

There are compelling data that clozapine has superior efficacy for
severely chronic and refractory schizophrenic inpatients. However, the
efficacy of clozapine in treatment-resistant outpatients has not been
established. Because of the anticipates growing use of clozapine among
outpatients, we propose to examine the efficacy and prediction of
response of clozapine in treatment-resistant schizophrenic outpatients.
After resistance to conventional neuroleptic treatment has been
confirmed, outpatients with chronic residual symptoms will participate
in a 10-week, double-blind parallel groups to study to determine the
effects of clozapine on levels of positive and negative symptoms and
functioning. Following the efficacy study, clozapine responders will be
followed for one year to accumulate data regarding the longterm effects
of clozapine on quality of life and course of illness. Brain
morphologic characteristics, determined by magnetic resonance imaging,
will be utilized to predict clozapine response. Clozapine-related
changes in positive and negative symptoms will be related to volumetric
measurements of the amygdala/hippocampus and the prefrontal cortex,
respectively. These data may provide new information about clozapine's
mechanism of action and the pathophysiology of schizophrenia.
StatusFinished
Effective start/end date4/1/9012/31/07

Funding

  • National Institutes of Health
  • National Institutes of Health: $259,296.00
  • National Institutes of Health

Fingerprint

Clozapine
Outpatients
Therapeutics
Amygdala
Prefrontal Cortex
Antipsychotic Agents
Inpatients
Hippocampus
Schizophrenia
Quality of Life
Magnetic Resonance Imaging

ASJC

  • Medicine(all)